Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin.
- Author:
Jian-Feng ZHOU
1
;
Chun-Mei BAI
;
Yue-Juan CHENG
;
Ning JIA
;
Ya-Juan SHAO
;
Shu-Chang CHEN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Camptothecin; administration & dosage; analogs & derivatives; Capecitabine; Colorectal Neoplasms; drug therapy; Deoxycytidine; administration & dosage; analogs & derivatives; Female; Fluorouracil; administration & dosage; analogs & derivatives; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; therapeutic use; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2009;31(3):358-361
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of irinotecan combined with xeloda (CAPIRI regimen) in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin.
METHODSTotally 38 patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin were enrolled. Patients received xeloda 1 000 mg/m2 orally twice daily on day 1 to 14 and intravenous irinotecan 100 mg/m2 on day 1 and 8 every 3 weeks.
RESULTSThe median age of 38 patients was 58.5 (27-77) years. CAPIRI regimen was used 11.0 (3.0-24.0) months after the diagnosis of metastatic colorectal cancer (CAPIRI regimen as second-line chemotherapy in 33 patients, third-line in 4 patients, and fourth-line in 1 patient). A total of 121 cycles of chemotherapy (median 3.0) were administered. Thirty-four patients were evaluable for response. The overall response rate and disease control rate were 5.9% and 61.8%, respectively. The median time to progression and overall survival were 4.5 months (95% CI, 3.4-5.6 months) and 11.0 months (95% CI, 10.2-11.8 months), respectively. All 38 patients were evaluable for safety. The most common adverse events were leukopenia (73.7%), neutropenia (65.8%), nausea and vomiting (60.5%), and diarrhea (28.9%). The occurrence rates of these grade 3-4 events were 10.5%, 13.2%, 10.5%, and 7.9%, respectively. All adverse events were tolerable.
CONCLUSIONCAPIRI regimen is effective and well-tolerated in Chinese patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin.
